Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?

Title

Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?

Creator

File Thomas M Jr; Marrie Thomas J

Publisher

Infectious disease clinics of North America

Date

2013
2013-03

Description

The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived contradictory results of published evidence. Studies evaluating the time to clinical recovery and the use of earlier endpoints for evaluation suggest that appropriate therapy provides a benefit if an atypical pathogen is a pathogen. Because recent surveillance studies suggest these pathogens are common and until there is the availability of accurate, cost-effective, and easily interpreted laboratory tests to provide the etiologic diagnosis at the time of point of care, empiric therapy of atypical pathogens is supported.

Subject

Anti-Bacterial Agents/*therapeutic use; Antibiotic Prophylaxis; Antibiotics – Therapeutic Use; Clinical Trials; Clinical Trials as Topic; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections – Microbiology; Community-Acquired Infections/drug therapy/microbiology; Humans; Pneumonia – Drug Therapy; Pneumonia – Microbiology; Pneumonia/*drug therapy/microbiology

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

99–114

Issue

1

Volume

27

Citation

File Thomas M Jr; Marrie Thomas J, “Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?,” NEOMED Bibliography Database, accessed September 28, 2021, https://neomed.omeka.net/items/show/3590.

Social Bookmarking